Perspective
Featured Topics
Lead story
Other featured articles
-
How to Protect Yourself Against Wildfire Smoke This Fire Season: Five Tips in Everyday Language
Helpful tips on staying protected from wildfire smoke.
Posted in -
Considerations in the Implementation of Multicancer Early Detection Tests
An analysis of the potential benefits and challenges of multi-cancer blood-based tests.
Posted in -
Addressing Regulatory Barriers to Buprenorphine Access at Retail Pharmacies
Regulations on buprenorphine are creating dispensing barriers at retail pharmacies that impact Americans with opioid use disorder.
Posted in -
Lack of Diversity in Clinical Trials Costs Billions of Dollars. Incentives Can Spur Innovation
Economic incentives to recruit more diverse participants for clinical trials are available and could save the U.S. billions of dollars.
Posted in
ADDITIONAL Perspectives
-
Bringing Back a Mask Mandate in Los Angeles County is Unjustified
Schaeffer Center experts argue in a recent op-ed that Los Angeles County hasn’t met the threshold for a mask mandate.
Categorized in -
Women and Adolescent Girls Face Barriers Accessing Birth Control and Plan B – Even in Blue States Like California
States dedicated to ensuring women receive the care they need should fix existing gaps in contraceptive access.
Categorized in -
The Supreme Court Left Millions of Americans Uninsured: Here’s What Congress Can Do to Cover Them
Congress can expand healthcare to millions of Americans by enrolling individuals in the 12 states that did not expand Medicaid.
-
The Cantwell-Grassley PBM Bill Is Much Needed But More Can Be Done
The proposed reforms are a helpful start, but could go further in addressing the lack of competition in the U.S. PBM market.
Categorized in -
Drugmakers Aren’t Driving Inflation
Drug prices have not experienced the major rise in cost like eggs or gasoline, and instituting price controls on drugs would only stifle medical innovation.
Categorized in -
PBMs Are Inflating the Cost of Generic Drugs. They Must Be Reined In
Anti-competitive practices and a lack of transparency in the generic drug market allow pharmacy benefit managers to profit off patients and payers.
Categorized in